ELEKTA RECEIVES ORDER TO DELIVER THE FIRST LEKSELL GAMMA KNIFE(R) PERFEXION™ TO INDIA


ELEKTA RECEIVES ORDER TO DELIVER THE FIRST LEKSELL GAMMA KNIFE(R) PERFEXION™ TO
INDIA

PRESS RELEASE
Stockholm, Sweden, May 2, 2007

Elekta today announced a new order from India for Leksell Gamma Knife®
Perfexion™, the world's most advanced system for non-invasive radiosurgery of
brain disorders including tumors, brain metastases and functional disorders. The
purchase decision is an important step in the effort to improve quality and
capacity of treatment of brain diseases for the entire northern part of India.
The order also demonstrates that Elekta has earned a strong reputation in one of
the most interesting emerging markets in the world as a company with
state-of-the-art technology and clinical solutions for treatment of cancer and
brain disorders.

The new order comes from Postgraduate Institute of Medical Education & Research
(PGIMER) in the city of Chandigarh, Punjab, a 1,400 bed multi specialty and
premier hospital providing state-of-the-art highly specialized care in all
branches of medical sciences including neurosurgery.

The purchase of Leksell Gamma Knife Perfexion will benefit a large number of
patients in Punjab, Uttar Pradesh, Haryana, Himachal Pradesh, Jammu & Kashmir,
as well as patients from other parts of the country who can now be treated with
this non-invasive state-of-the-art technology for treating various brain
disorders including brain metastases.

“We are honored to receive this prestigious assignment”, comments Tomas Puusepp,
President & CEO of Elekta. “The order to install Leksell Gamma Knife Perfexion
at PGIMER is to a large extent the result of the ability of this new system to
streamline and speed up the radiosurgery procedures at high volume sites. Since
its introduction a year ago, we have seen high interest in Leksell Gamma Knife
Perfexion from neurosurgeons and radiation oncologists worldwide and the demand
has been high, particularly in the recent months”, Tomas Puusepp concludes.

PGIMER is a tertiary level institute which was established in 1962 by an Act of
Parliament. It was the vision of the Chief Minister of Punjab (Mr. Pratap Singh
Kairon) and the Prime Minister of India (Pandit Jawahar Lal Nehru) which
resulted in this institute being created. PGIMER is a ‘not-for-profit'
organization funded by the Central Government and the credo of the Institute is
- “Patient Care, Teaching, and Research”. The Neurosurgery Department of PGIMER
is one of the most advanced neurosurgical centers in the country with over 3,000
neurosurgical procedures performed per year. The workload in the Dept. of
Neurosurgery has increased by almost 60 percent over the last five years and the
waiting list for surgery is becoming longer.  


With the new Leksell Gamma Knife installed, PGIMER will be able to treat a large
number of patients who can return to normal life immediately after treatment
without the risk of infection or other complications associated with open brain
surgery. This will lead to more hospital beds being available for those patients
requiring open surgery. The delivery of the equipment is expected to be made in
early 2008. 

“India is one of the fastest growing and emerging economies in the world with an
increasing demand and a need for more cost efficient healthcare solutions. We
are very pleased with this new order and we see this as a result of our
long-term commitment to India which has the potential and demand for quality
products in both radiation therapy and neurosciences. With a strong Elekta team
and service organization in place, we are well equipped to serve both existing
and potential new customers in this growing market”, says Percy Shroff, Managing
Director, Elekta India.

Elekta has been supplying clinical solutions to India for more than 10 years and
has a strong customer base in the country with numerous installations of Leksell
Gamma Knife®, Leksell® Stereotactic System and linear accelerators. The Elekta
office is located in New Delhi with sales and service personnel operating
directly from strategic locations around the country. 

Gamma Knife® surgery 

Gamma Knife surgery is a non-invasive method for treating brain disorders. It is
defined as the delivery of a single, high dose of radiation to a small and
critically located intracranial volume through the intact skull. After Gamma
Knife surgery, the patient normally leaves the hospital the same or the
following day, making it a very cost effective alternative to open surgery. 

Since its introduction, Leksell Gamma Knife has revolutionized the treatment of
brain disorders. Today, this treatment is offered by hundreds of leading
hospitals and clinics around the world. Around 50,000 patients undergo Gamma
Knife surgery every year, and this unique procedure has earned an outstanding
scientific track record with thousands of peer reviewed articles on treatment
efficacy, improved quality of life for patients and cost efficiency.







For further information, please contact:

Peter Ejemyr
Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile)
e-mail: peter.ejemyr@elekta.com  
Percy Shroff
Managing Director, Elekta India
Tel: +91 124 46 33 222
e-mail: percy@elektaindia.com 


About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com. 

Attachments

05022078.pdf
GlobeNewswire